Your browser is no longer supported. Please, upgrade your browser.
Paratek Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own6.30% Shs Outstand47.12M Perf Week-0.21%
Market Cap239.12M Forward P/E21.01 EPS next Y0.23 Insider Trans-4.95% Shs Float44.76M Perf Month-5.17%
Income-54.50M PEG- EPS next Q-0.46 Inst Own54.20% Short Float10.31% Perf Quarter-31.95%
Sales103.60M P/S2.31 EPS this Y44.40% Inst Trans1.45% Short Ratio9.60 Perf Half Y-34.39%
Book/sh-2.11 P/B- EPS next Y125.60% ROA-30.50% Target Price- Perf Year-25.12%
Cash/sh1.50 P/C3.18 EPS next 5Y- ROE54.40% 52W Range4.51 - 11.23 Perf YTD-23.80%
Dividend- P/FCF- EPS past 5Y12.60% ROI-52.50% 52W High-57.81% Beta1.55
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin83.10% 52W Low5.10% ATR0.26
Employees196 Current Ratio7.30 Sales Q/Q518.30% Oper. Margin-34.70% RSI (14)34.56 Volatility4.45% 4.53%
OptionableYes Debt/Eq- EPS Q/Q137.60% Profit Margin-52.60% Rel Volume0.36 Prev Close4.77
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout- Avg Volume480.48K Price4.74
Recom1.50 SMA20-8.35% SMA50-12.25% SMA200-31.92% Volume26,588 Change-0.63%
Apr-23-21Upgrade WBB Securities Speculative Buy → Buy $6 → $10
Mar-02-21Initiated Jefferies Buy $15
Nov-09-20Reiterated H.C. Wainwright Buy $19 → $22
Jan-08-20Initiated WBB Securities Speculative Buy $6
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
Mar-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-24-17Initiated Guggenheim Buy $44
Jul-18-17Reiterated H.C. Wainwright Buy $36 → $43
May-19-17Initiated Raymond James Strong Buy
Apr-11-17Reiterated H.C. Wainwright Buy $33 → $36
Apr-04-17Reiterated Wedbush Outperform $30 → $34
Apr-04-17Initiated Wedbush Outperform $30
Oct-27-16Resumed Leerink Partners Outperform $23
Jun-17-16Reiterated H.C. Wainwright Buy $31 → $34
May-13-16Initiated Robert W. Baird Outperform $30
Mar-30-16Resumed Cantor Fitzgerald Buy $27
Feb-29-16Initiated H.C. Wainwright Buy $32
Jul-22-15Initiated Gabelli & Co Buy $34
Sep-09-21 08:30AM  
Sep-01-21 04:05PM  
Aug-19-21 12:14PM  
Aug-18-21 04:12PM  
Aug-10-21 04:25AM  
Aug-09-21 05:35PM  
Aug-05-21 08:00AM  
Aug-04-21 04:30PM  
Aug-03-21 04:30PM  
Aug-02-21 04:35PM  
Jun-29-21 08:00AM  
Jun-16-21 12:29PM  
Jun-14-21 08:00AM  
Jun-11-21 06:54AM  
Jun-10-21 08:00AM  
Jun-09-21 10:25AM  
Jun-08-21 11:07AM  
Jun-01-21 06:36PM  
May-26-21 04:17PM  
May-17-21 10:00PM  
May-10-21 04:05PM  
May-03-21 04:01PM  
Apr-12-21 01:59PM  
Apr-01-21 04:01PM  
Mar-01-21 04:01PM  
Feb-25-21 12:01AM  
Feb-24-21 04:01PM  
Feb-18-21 04:01PM  
Feb-17-21 04:01PM  
Feb-10-21 12:06AM  
Feb-08-21 08:00AM  
Feb-01-21 04:05PM  
Jan-06-21 08:00AM  
Jan-04-21 05:00PM  
Dec-25-20 04:07AM  
Dec-10-20 09:40PM  
Dec-01-20 04:05PM  
Nov-12-20 04:01PM  
Nov-05-20 06:35PM  
Nov-02-20 04:05PM  
Oct-29-20 12:35PM  
Oct-27-20 08:00AM  
Oct-26-20 02:52PM  
Oct-21-20 08:00AM  
Sep-09-20 04:01PM  
Sep-01-20 04:05PM  
Aug-25-20 10:17AM  
Aug-10-20 08:45AM  
Aug-05-20 04:01PM  
Aug-03-20 04:05PM  
Jul-28-20 04:01PM  
Jul-05-20 03:05PM  
Jun-12-20 04:46PM  
May-29-20 08:30AM  
May-28-20 08:00AM  
May-11-20 04:05PM  
Apr-30-20 08:00AM  
Apr-28-20 12:14PM  
Apr-14-20 12:26PM  
Apr-02-20 08:00AM  
Apr-01-20 08:00AM  
Mar-14-20 10:55AM  
Mar-10-20 05:12PM  
Mar-02-20 04:05PM  
Feb-27-20 11:50AM  
Feb-26-20 08:00AM  
Feb-25-20 05:35PM  
Feb-24-20 07:00AM  
Feb-17-20 01:36PM  
Feb-13-20 04:01PM  
Jan-14-20 03:12PM  
Dec-20-19 08:38AM  
Dec-19-19 09:33PM  
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Loh EvanCEOAug 17Sale5.1233,931173,7271,000,360Aug 18 07:29 PM
Haskel William M.CLO, General Counsel & Sec.Aug 17Sale5.129,69249,623370,525Aug 18 07:22 PM
BIGHAM MICHAELExec. Chairman of the BoardAug 17Sale5.1232,030163,994922,282Aug 18 07:16 PM
Brenner Randall B.Chief Development & RegulatoryAug 17Sale5.128,76644,882281,424Aug 18 07:14 PM
Woodrow AdamPresident & Chief CommercialAug 17Sale5.1210,97556,192501,321Aug 18 07:11 PM
Woodrow AdamPresident & Chief CommercialJun 04Sale9.7017,182166,665474,796Jun 08 07:34 PM
Haskel William M.CLO, General Counsel & Sec.Jun 04Sale9.707,56173,342357,092Jun 08 07:32 PM
Brenner Randall B.Chief Development & RegulatoryJun 04Sale9.709,97896,787268,940Jun 08 07:30 PM
BIGHAM MICHAELExec. Chairman of the BoardJun 04Sale9.7034,364333,331879,312Jun 08 07:28 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 14Sale6.7126,063174,883546,517Dec 15 07:47 PM
Brenner Randall B.Chief Development & RegulatoryDec 14Sale6.718,76058,780128,782Dec 15 07:50 PM
Haskel William M.CLO, General Counsel & Sec.Dec 14Sale6.716,84245,910203,267Dec 15 07:52 PM
Woodrow AdamPresident & Chief CommercialDec 14Sale6.7112,85586,257271,273Dec 15 07:54 PM
Loh EvanCEODec 14Sale6.7126,415177,245600,559Dec 15 07:56 PM
Loh EvanCEODec 11Sale6.9518,585129,166626,974Dec 15 07:56 PM
Woodrow AdamPresident & Chief CommercialDec 11Sale6.959,04562,863284,128Dec 15 07:54 PM
Haskel William M.CLO, General Counsel & Sec.Dec 11Sale6.954,81433,457210,109Dec 15 07:52 PM
Brenner Randall B.Chief Development & RegulatoryDec 11Sale6.956,16442,840137,542Dec 15 07:50 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 11Sale6.9518,337127,442572,580Dec 15 07:47 PM
Loh EvanCEONov 13Sale5.9320,928124,103645,559Nov 16 06:36 PM
Brenner Randall B.Chief Development & RegulatoryNov 13Sale5.938,35749,557143,706Nov 16 06:33 PM
BIGHAM MICHAELExec. Chairman of the BoardNov 13Sale5.9326,250155,662590,917Nov 16 06:30 PM
Haskel William M.CLO, General Counsel & Sec.Nov 13Sale5.936,89240,870214,923Nov 16 06:28 PM
Woodrow AdamPresident & Chief CommercialNov 13Sale5.9315,00088,950293,173Nov 16 06:23 PM
Loh EvanCEOOct 29Option Exercise4.3039,479169,760591,487Nov 02 04:50 PM